ProCE Banner Activity

LUNA 3: Phase III Trial of Rilzabrutinib vs Placebo in Patients Aged ≥18 Yr With Persistent/Chronic Primary ITP

Conference Coverage
Slideset

The phase III LUNA 3 trial demonstrated superior efficacy with BTK inhibitor rilzabrutinib compared with placebo in patients with previously treated persistent/chronic primary ITP.

Released: December 11, 2024

Expiration: December 10, 2025

Share

Provided by

Provided by Clinical Care Options, LLC.

ProCE Banner

Supporters

This educational activity is supported by independent medical educational grants from AstraZeneca, Bristol Myers Squibb, GlaxoSmithKline, Incyte Corporation, Lilly, and Novartis Pharmaceuticals Corporation.

AstraZeneca

Bristol Myers Squibb

GlaxoSmithKline

Incyte Corporation

Lilly

Novartis Pharmaceuticals Corporation